María Jesús Rubio

1.7k total citations
48 papers, 693 citations indexed

About

María Jesús Rubio is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, María Jesús Rubio has authored 48 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Reproductive Medicine, 16 papers in Oncology and 14 papers in Obstetrics and Gynecology. Recurrent topics in María Jesús Rubio's work include Ovarian cancer diagnosis and treatment (36 papers), Endometrial and Cervical Cancer Treatments (12 papers) and PARP inhibition in cancer therapy (11 papers). María Jesús Rubio is often cited by papers focused on Ovarian cancer diagnosis and treatment (36 papers), Endometrial and Cervical Cancer Treatments (12 papers) and PARP inhibition in cancer therapy (11 papers). María Jesús Rubio collaborates with scholars based in Spain, Italy and Germany. María Jesús Rubio's co-authors include Francisco Cristobal Muñoz‐Casares, Sebastián Rufián, Jordi Muntané, Antonio González-Martı́n, Andrés Redondo, Carlos Jerjes‐Sánchez, María Carmen Muñoz-Villanueva, Álvaro Arjona‐Sánchez, Enrique Aranda and Isabel Bover and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

María Jesús Rubio

45 papers receiving 675 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
María Jesús Rubio Spain	16	506	344	214	180	102	48	693
G. P. Breitbach Germany	10	413 0.8×	330 1.0×	239 1.1×	222 1.2×	18 0.2×	36	685
Ram Eitan Israel	16	382 0.8×	236 0.7×	276 1.3×	133 0.7×	18 0.2×	73	805
Ulrich Canzler Germany	13	528 1.0×	303 0.9×	196 0.9×	226 1.3×	12 0.1×	48	683
U. Metzger France	14	267 0.5×	282 0.8×	227 1.1×	76 0.4×	38 0.4×	46	658
K. Wollschlaeger Germany	7	461 0.9×	296 0.9×	182 0.9×	153 0.8×	14 0.1×	11	555
Jerome T. O’Connell United States	7	162 0.3×	207 0.6×	104 0.5×	123 0.7×	83 0.8×	8	496
Stephen Dobbs United Kingdom	9	994 2.0×	657 1.9×	557 2.6×	205 1.1×	14 0.1×	16	1.2k
Tito Lopes United Kingdom	5	938 1.9×	615 1.8×	491 2.3×	206 1.1×	13 0.1×	7	1.0k
Jonathan Herod United Kingdom	7	1.0k 2.0×	623 1.8×	576 2.7×	232 1.3×	12 0.1×	8	1.2k
Ricardo Sáinz de la Cuesta Spain	12	587 1.2×	125 0.4×	358 1.7×	114 0.6×	11 0.1×	23	831

Countries citing papers authored by María Jesús Rubio

Since Specialization

Citations

This map shows the geographic impact of María Jesús Rubio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María Jesús Rubio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María Jesús Rubio more than expected).

Fields of papers citing papers by María Jesús Rubio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María Jesús Rubio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María Jesús Rubio. The network helps show where María Jesús Rubio may publish in the future.

Co-authorship network of co-authors of María Jesús Rubio

This figure shows the co-authorship network connecting the top 25 collaborators of María Jesús Rubio. A scholar is included among the top collaborators of María Jesús Rubio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María Jesús Rubio. María Jesús Rubio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rubio, María Jesús, Aránzazu Manzano, Purificación Estévez-García, et al.. (2024). Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study. BMC Cancer. 24(1). 803–803.

Marth, Christian, Richard D. Moore, Mariusz Bidziński, et al.. (2024). Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study. Gynecologic Oncology. 190. S63–S64.

Tavira, Beatriz, Luís Manso, Ana Santaballa, et al.. (2023). Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study). Clinical Cancer Research. 30(1). 176–186. 6 indexed citations

Redondo, Andrés, Maria-Pilar Barretina-Ginesta, José Alejandro Pérez Fidalgo, María Jesús Rubio, & Antonio González-Martı́n. (2023). Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus. Journal of Gynecologic Oncology. 34(5). e57–e57. 2 indexed citations

Marth, Christian, Marie‐Ange Mouret‐Reynier, Domenica Lorusso, et al.. (2023). #528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial. A21.1–A21. 7 indexed citations

Poveda, Andrés, Raquel López-Reig, Ana Oaknin, et al.. (2022). Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers. 14(4). 915–915. 5 indexed citations

Redondo, Andrés, Regina Gironés, María Iglesias, et al.. (2021). Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study). European Journal of Gynaecological Oncology. 42(6). 1116–1116. 1 indexed citations

Fidalgo, José Alejandro Pérez, Alfonso Cortés, Yolanda García García, et al.. (2020). 832P GEICO1601-ROLANDO trial: A multicentric single arm phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer. Annals of Oncology. 31. S626–S626. 1 indexed citations

Mirza, Mansoor Raza, Line Bjørge, Frederik Marmé, et al.. (2020). LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial. Annals of Oncology. 31. S1160–S1160. 52 indexed citations

10.

Redondo, Andrés, María Jesús Rubio, Yolanda García García, et al.. (2020). SEOM clinical guidelines for cervical cancer (2019). Clinical & Translational Oncology. 22(2). 270–278. 16 indexed citations

11.

Rubio, María Jesús, María José Lecumberri, Jesús Alarcón, et al.. (2020). Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO). Gynecologic Oncology Reports. 33. 100594–100594. 11 indexed citations

12.

Minig, Lucas, Sílvia Cabrera, María Jesús Rubio, et al.. (2018). Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study. Clinical & Translational Oncology. 20(10). 1337–1344. 15 indexed citations

13.

Oaknin, Ana, María Jesús Rubio, Andrés Redondo, et al.. (2015). SEOM guidelines for cervical cancer. Clinical & Translational Oncology. 17(12). 1036–1042. 26 indexed citations

14.

Muñoz‐Casares, Francisco Cristobal, Francisco Fernández, Álvaro Arjona‐Sánchez, et al.. (2015). Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center. European Journal of Surgical Oncology. 42(2). 224–233. 42 indexed citations

15.

Konecny, Gottfried E., Neil J. Finkler, Agustin A. García, et al.. (2013). Dovitinib as second-line therapy in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or non-mutated advanced and/or metastatic endometrial cancer (EC): A single-arm, multicenter, phase II study.. Journal of Clinical Oncology. 31(15_suppl). TPS5616–TPS5616. 2 indexed citations

16.

González-Martı́n, Antonio, Andrés Redondo, M. Jurado, et al.. (2013). GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clinical & Translational Oncology. 15(7). 509–525. 9 indexed citations

17.

Muñoz‐Casares, Francisco Cristobal, Sebastián Rufián, María Jesús Rubio, et al.. (2009). The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clinical & Translational Oncology. 11(11). 753–759. 59 indexed citations

18.

Poveda, Andrés, Ramón Salazar, C. Mendiola, et al.. (2007). Update in the management of ovarian and cervical carcinoma. Clinical & Translational Oncology. 9(7). 443–451. 15 indexed citations

19.

Muñoz‐Casares, Francisco Cristobal, Sebastián Rufián, María Jesús Rubio, et al.. (2007). Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clinical & Translational Oncology. 9(10). 652–662. 25 indexed citations

20.

González-Martı́n, Antonio, Isabel Bover, María Jesús Rubio, et al.. (2005). Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study. Annals of Oncology. 16(5). 749–755. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact